sometime in the last few weeks Anteotech has added a papers and publications section to the resource room section of their website. they also added 3 division of anteo products, biosensor , microspheres and nano kit to show which product is used in each publication.
https://www.anteotech.com/resources/?resource-type=papers-publications#filterall involve our lifescience products. in the agm presentation we had 12 companies we were working with, towards commercial deals. i reckon here are a few
1/ Abingdon Health
I know tpain posted this previously but I don't think many saw it, published dec 15th
https://www.abingdonhealth.com/innovation-in-labels-driving-use-of-lateral-flow-technology/"Label selection should be a critical element of any lateral flow development process. In this blog
Charlotte Howard, R&D Lead Scientist at leading lateral flow CRO and CDMO Abingdon Health, outlines why innovation in lateral flow is driving the expanding use of lateral flow products and technology across a range of sectors."
"
Anteobind™ is new to the market providing an alternative to conventional carboxyl conjugation, making use of a polymeric metal ion complex
(3). However, while covalent interactions are used to improve label conjugation, they target specific amino acids with carboxyl groups.
As such, sometimes the Fc region or the Fab region can attach to the colloid and, therefore, the orientation is not optimal for exposing the binding site of the antibody resulting in lower sensitivity. The metal-ion complex of Anteobind™ allows a flexibility of the binding molecules without breaking away from the surface, focusing on binding to the histidine cluster in the Fc region of the antibody resulting in a preferential orientation of the antibody and allowing more access for sample interaction, thereby increasing sensitivity."
it quoted a publication in the above from 2022, basically testing anteobind biosensor
https://www.mdpi.com/2079-6374/12/3/1402/ Serum Institute of India
we know they have made an initial order of $260K. I initially thought it was for vaccine batch testing but could it be for more. we have these 2 publications. have been posted before by jandb85
View attachment 5847847"Therefore, there is an urgent need to characterize existing reference standards for the standardization of multiplex immunoassays (MIAs)."
why are the serum institute of india and the UK MHRA working on stds for muliplex immunoassays comparing results from luminex beads and anteobind?
in the 2 papers the study were in accordance with FDA, EMA, ICH10 and MHRA guidelines
https://www.anteotech.com/wp-conten...opment-and-validation-of-bead-based-assay.pdfhttps://www.anteotech.com/wp-conten...ntification-of-human-serum-IgG-antibodies.pdf3/ Merck
I've given plenty of connection b/w anteotech and Merck over the years. their membrane plant is moving forward. deals will have to be signed relatively soon
View attachment 5847844 battery deals are the more prominent focus of deals being signed but lifescience could surprise in the new year. it's part of the beauty of being invested in ADO having 2 possible revenue producing divisions at this stage of their progression.
it's not just hope, plenty evidence IMO that 2024 will be the year for ADO.
GLTAH, DYOR, IMO etc etc
(20min delay)
